In addition, we clearly did not include enough patients with ALK-rearranged and EGFR-mutated NSCLC (n = 3 and 17 respectively) to assess the impact of these mutations on the presence of brain metastases and the course of their disease. This evidence concerns the gene ALK and non-small cell lung carcinoma.